CSCO Annual Meeting Interview Listening to Professor Ye Dingwei and He Zhisong's Interpretation of Diagnosis, Treatment and Management of Prostate Cancer

*Only for medical professionals to read and comment on the status quo of prostate diagnosis and treatment, and talk about the progress of prostate cancer drug treatment, full-course management and precise treatment
.

In recent years, the incidence of urinary system tumors in China has increased rapidly, and it has become an important disease threatening the health of Chinese people
.

Among urinary system tumors, prostate cancer has long been regarded as a relatively rare urinary system tumor, with a higher incidence in Western countries
.

However, in recent years, the incidence of prostate cancer in China has been increasing, which has attracted more and more attention
.

The 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Conference have been officially held on September 25.
The seminar in the field of prostate cancer has attracted the attention of the industry and will undoubtedly bring about changes in the diagnosis and treatment of prostate cancer
.

The Medical Oncology Channel specially invited Professor Ye Dingwei from Fudan University Cancer Hospital and Professor He Zhisong from Peking University First Hospital to explain their academic opinions to clinicians on the relevant progress in the field of prostate cancer diagnosis and treatment in the CSCO Annual Conference
.

Professor Ye Dingwei’s wonderful video The incidence of prostate cancer is increasing year by year.
Early screening and early treatment is the key.
Shanghai has ranked fifth among male malignant tumors [1]
.

The overall mortality of Chinese men with prostate cancer is on the rise [2], and the 5-year survival rate is not satisfactory, only 30% [3]
.

When prostate cancer patients in our country are first diagnosed, most of them are already in the advanced stage [4]
.

Therefore, screening, early diagnosis and treatment of high-risk groups are effective means to improve the overall survival rate of prostate cancer patients in China
.

Professor He Zhisong said that the year-on-year increase in the incidence of prostate cancer in China is mainly based on the increasingly serious problem of population aging, people's awareness of disease screening, and the country's strong support for public medical and health institutions
.

At present, the level of diagnosis and treatment in China is developing rapidly, and the level of diagnosis and treatment in big cities is no less than the international level.
Domestic biopharmaceuticals are developing very rapidly.
Whenever new drugs appear on the market in the world, the country can quickly keep up with the pace of R&D and listing
.

However, the diagnosis and treatment situation in various regions in the country is unbalanced.
In cities with more developed economy, patients' willingness to seek medical treatment is stronger, resulting in more patients diagnosed and a higher proportion of early-stage patients
.

Professor Zhisong He’s wonderful video CRPC treatment is progressing rapidly, and many drugs are "striving for beauty".
Because prostate cancer is a hormone-dependent disease, anti-hormonal therapy plays an important role in the treatment of prostate cancer.
Among them, androgen deprivation therapy (ADT) It is the most common hormone treatment option
.

However, most patients will eventually develop castration-resistant prostate cancer (CRPC), and metastatic castration-resistant prostate cancer (mCRPC) is the main cause of death for prostate cancer
.

Professor Zhisong He summarized the progress of CRPC drug treatment.
He pointed out: At present, domestic chemotherapy drugs have achieved certain curative effects in the treatment of CRPC, but the single treatment method and the lack of effective follow-up treatment methods after treatment failure have always been the treatment of CRPC patients.
Difficult
.

In recent years, with people's further understanding and in-depth understanding of the mechanism of CRPC, new endocrine drugs and androgen receptor (AR) inhibitors have been developed, and the treatment situation has been comprehensively improved
.

At present, some new endocrine drugs and AR inhibitors have entered the national medical insurance, and the availability of drugs has been greatly improved
.

How to better promote the development of precision treatment of prostate cancer in China Nowadays, in the context of the emergence of more and more new drugs, how to better plan the entire management and precision treatment is a major clinical test
.

Professor Ye Dingwei said that in recent years, major domestic clinical associations and academic groups have promoted standardized and precise treatment of prostate cancer
.

Prostate cancer pays more and more attention to divide and treat, and molecular classification is used to classify patients to determine the subsequent diagnosis and treatment methods-which patients are suitable for active monitoring and which patients need more active treatment
.

In the future, the treatment plan may no longer be divided in a simple first-line and second-line way, but a more precise sequential treatment based on different types of patients
.

Researchers in China should actively carry out clinical research on new drugs.
For innovative drugs with clear curative benefits, they should actively promote the approval and listing of innovative drugs and the inclusion of medical insurance
.

In the field of tumor diagnosis and treatment, the concept of multidisciplinary team (MDT) collaboration has been deeply rooted in the hearts of the people, actively using advanced technology and equipment and treatment methods to strengthen early diagnosis and early treatment, actively carrying out MDT diagnosis and treatment, and improving academic communication and clinical practice capabilities, online and online Combining with the central city to drive the participation of surrounding regional hospitals, comprehensively improve the level of diagnosis and treatment of prostate cancer, and promote the development of domestic precision treatment of prostate cancer
.

Improving the standardized treatment and patient follow-up diagnosis and treatment in primary hospitals and escorting patients.
Primary medical institutions are the real main battlefield for the prevention and control of prostate cancer.
In order to improve the prognosis of prostate cancer patients, Professor Ye Dingwei puts forward several suggestions: Strengthen the treatment of the prostate by the frontline medical staff.
The importance of cancer, the training of grassroots medical staff through a combination of online and offline methods, grassroots hospital doctors can actively participate in academic conferences, such as the Chinese Anti-Cancer Association's Urinary and Male Reproductive Tumor Professional Committee ( CACA-GU) Academic Annual Meeting
.

Primary-level medical staff can carry out prostate cancer health education, encourage patients to take the initiative to seek medical care, and healthy people take the initiative to check, and further utilize the advantages of primary medical services to improve the early diagnosis of prostate cancer, thereby improving the prognosis of patients
.

Prostate cancer itself is a disease with a relatively long natural course, which indicates that follow-up work is very important
.

Now entering the post-epidemic era, Professor He Zhisong believes that this has little impact on the follow-up diagnosis and treatment of cancer patients
.

One way of follow-up is in the outpatient clinic, and the other is to rely on modern methods such as information technology, the Internet, and smartphones, which can reduce time and improve efficiency.
This is a common follow-up method for cancer patients in the post-epidemic era
.

Now whether it is popular science propaganda or follow-up communication, it can be through the ubiquitous network
.

In the follow-up process, through the cooperation of patients, family members, and doctors to combat prostate cancer, better results may be achieved
.

References: [1].
Wang Yejing, Fu Zhongxing, Wang Jue, et al.
Analysis of the incidence and mortality of prostate cancer in community population in Luwan District, Shanghai from 2004 to 2011[J].
Chinese Cancer, 2017, 026(006):438-441 .
[2].
Ding Yanni,Liu Qing,Zhang Qingjun.
The mortality trend of Chinese male prostate cancer from 1992 to 2017:APC model analysis[J].
Public Health and Preventive Medicine,2020,31(1):25-28.
[ 3].
Zeng Qingpei.
Prostate cancer “latent” and betrays men’s health[J].
Family Medicine, 2012(5):19.
[4].
He Jingliang, He Leye.
Progress in the treatment of hormone-resistant prostate cancer[J].
Modern Journal of Genitourinary Oncology, 2012, 4(6):358-358.
Statement: This material is supported by AstraZeneca and is only for reference by medical and health professionals.
Approval number: CN-866214 Validity: November 18, 2021*This article It is only used to provide scientific information to medical professionals and does not represent the views of this platform